SGLT2i
SGLT2i is a pharmaceutical drug with 7 clinical trials. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
HF Patients With LVADs Being Treated With SGLT2i
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Clinical Trials (7)
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
HF Patients With LVADs Being Treated With SGLT2i
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7